Elevated serum levels of p105(erbB-2) in patients with advanced-stage prostatic adenocarcinoma

International Journal of Cancer

Volumn 69, Issue 5, 1996, Pages 398-402

  Myers, Russell B ^a   Brown, David ^b   Oelschlager, Denise K ^a   Waterbor, John W ^b   Ernest Marshall, M ^c   Srivastava, Sudhir ^e   Stockard, Cecil R ^a   Urban, Donald A ^d   Grizzle, William E ^a  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c University of Alabama at Birmingham   (United States)

^d Kentucky   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOPROTEIN;

ADENOCARCINOMA; ADVANCED CANCER; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; ONCOGENE C ERB; PRIORITY JOURNAL; PROSTATE CARCINOMA;

ADENOCARCINOMA; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; NF-KAPPA B; NF-KAPPA B P50 SUBUNIT; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC DISEASES; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; PROTEIN PRECURSORS; RECEPTOR, ERBB-2;

EID: 0029828592     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19961021)69:5<398::AID-IJC8>3.0.CO;2-0     Document Type: Article

References (29)

1. BACUS, S.S., HUBERMAN, E., CHIN, D., KIGUCHI, K., SIMPSON, S., LIPPMAN, M. and LUPU, R., A ligand for the erbB-2 oncogene product (gp30) induces differentiation of human breast cancer cell Cell Growth Differentiation, 3, 401-411 (1992).
2. BERCHUCK, A. and 13 OTHERS, Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res., 50, 4087-4091 (1990).
3. BORG, A., TANDON, A.K., SIGURDSSON, H., CLARK, G.M., FERNO, F., FUQUA, S.A.W., KILLANDER, D. and MCGUIRE, W.L., HER-2/neu amplification predicts poor survival in node positive breast cancer. Cancer Res., 50, 4332-1337 (1990).
4. COUSSENS, L., YANG-FENG, T.L., LIAO, Y.C., CHEN, E., GRAY, A., MCGRATH, J., SEEBURG, P.H., LIBERMANN, T.A., SCHLESSINGER, J., FRANCKE, U., LEVINSON, A. and ULLRICH, A., Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science, 230, 1132-1139 (1985).
5. DE POTTER, C.R., QUATACKER, J., MAERTENS, G., VAN DAELE, S., PAUWELS, C., VERHOFSTEDE, C., ESCHAUTE, W. and ROELS, H., The subcellular localization of the neu protein in human normal and neoplastic cells. Int. J. Cancer, 44, 969-974 (1989).
6. DI FIORE, P.P., PIERCE, J.H., KRAUS, H., SEGATTO, O., KING, C.R. and AARONSON, S.A., erbB-2 is a potent oncogene when overexpressed in NIH-3T3-cell. Science, 237, 178-182 (1987).
7. GATANAGA, T., HWANG, C., KOHR, W., CAPPUCINI, F., LUCCI, J.A. III, JEFFES, E.W., LENTZ, R., TOMICH, J., YAMAMOTO, R.S. and GRANGER, G.A., Purification and characterization of an inhibitor (soluble tumor necrosis factor receptor) for tumor necrosis factor and lymphotoxin obtained from the serum ultrafiltrates of human cancer patients. Proc. nat. Acad. Sci. (Wash.), 87, 8781-8784 (1990).
8. neu) in prostate tumors: an immunohistochemical study. Prostate, 23, 329-336 (1993).
9. GLEASON, D.F. and MELLINGER, G.T. and THE VETERANS ADMINISTRATION CO-OPERATIVE UROLOGICAL RESEARCH GROUP, Prediction of prognosis for prostatic adenocarcinoma and combined histological grading and clinical staging. J. Urol., 111, 58-64 (1974).
10. GRIZZLE, W.E., MYERS, R.B., ARNOLD, M.M. and SRIVASTAVA, S., Evaluation of biomarkers in breast and prostate cancers. J. cell. Biochem., 19 (Suppl.), 259-266 (1994).
11. erbB-2. Science, 256, 1205-1210 (1992).
12. KYNAST, B., BINDER, L., MARX, D., ZOLL, B., SCHMOLL, H.J., OELLERICH, M. and SCHAUER, A., Determination of a fragment of the c-erbB-2 translational product in serum of breast cancer patients. J. Cancer Res. clin. Oncol., 119, 249-252 (1993).
13. LEITZEL, K., TERAMOTO, Y., SAMPSON, E., MAUCERI, J., LANGTON, B.C., DEMERS, L., PODCZASKI, E., HARVEY, H., SHAMBAUGH, S., VOLAS, G., WEAVER, S. and LIPTON, A., Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients. J. clin. Oncol., 10, 1436-1443 (1992).
14. MCCANN, A., DERVAN, P.A., JOHNSTON, P.A., GULLICK, W.J. and CARNEY, D.N., c-erbB-2 oncoprotein expression in primary human tumors. Cancer, 65, 88-92 (1990).
15. MELLON, K., THOMPSON, S., CHARTON, R.G., MARSH, C., ROBINSON, M., LANE, D.P., HARRIS, A.L., WILSON-HORNE, C.H. and NEAL, D.E., p53, c-erbB-2 and the epidermal growth factor receptor in the benign and malignant prostate. J. Urol., 147, 496-499 (1992).
16. erbB-2 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. J. nat. Cancer Inst., 86, 1140-1145 (1994).
17. erbB-4. Nature (Lond.), 366, 473-475 (1993).
18. PRESS, M.F., HUNG, G., GODOLPHIN, W. and SLAMON, D.J., Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res., 54, 2771-2777 (1994).
19. SADASIVAN, R., MORGAN, R., JENNINGS, S., AUSTENFELD, M., VAN VELDHUIZEN, P., STEPHENS, R. and NOBLE, M., Overexpression of HER-2/NEU may be an indicator of poor prognosis in prostate cancer. J. Urol., 150, 126-131 (1993).
20. SLAMON, D.J., CLARK, G.M., WONG, S.G., LEVIN, W.J., ULLRICH, A. and MCGUIRE, W.L., Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science, 235, 177-182 (1987).
21. SLAMON, D.J., GODOLPHIN, W., JONES, L.A., HOLT, J.A., WONG, S.G., KEITH, D.E., LEVIN, W.J., STUART, S.G., UDOVE, J., ULLRICH, A. and PRESS, M.F., Studies of HER-2/neu proto-oncogene in human breast and ovarian cancer. Science, 244, 707-712 (1989).
22. SLIWKOWSKI, M.X., SCHAEFER, G., AKITA, R.W., LOFGREN, J.A., FITZPATRICK, V.D., NUIGENS, A., FENDLY, B.M., CERIONE, R.A., VANDLEN, R.L. and CARRAWAY, K.L. III, Coexpression of erbB-2 and erbB-3 proteins reconstitutes a high affinity receptor for heregulin. J. biol. Chem., 269, 14661-14665 (1994).
23. VELTRI, R.W., PARTIN, A.W., EPSTEIN, J.E., MARLEY, G.M., MILLER, G.M., SINGER, D.S., PATTON, K.P., CRILEY, S.R. and COFFEY, D.S., Quantitative nuclear morphometry, markovian texture descriptors and DNA content captured on a CAS-200 image analysis system, combined with PCNA and HER-2-NEU immunohistochemistry for prediction of prostate cancer progression. J. cell. Biochem., Suppl. 19, 249-258 (1994).
24. WARE, J.L., MAYGARDEN, S.J., KOONTZ, W.W. and STROM, S.C., Immunohistochemical detection of c-erbB-2 protein in human benign and neoplastic prostate. Hum. Pathol., 22, 254-258 (1991).
25. WEN, D., PELES, E., CUPPLES, R., SUGGS, S.V., BACUS, S.S., LUO, Y., TRAIL, G., HU, S., SILBIGER, S.M., LEVY, R.B., KOSKI, R.A., LU, H.S. and YARDEN, Y., Neu differentiation factor: an EGF domain and an immunoglobulin homology unit. Cell, 69, 559-572 (1992).
26. WRIGHT, G.L., GROB, M., HUANG, C.L., TROYER, J., ADAM, B.L., CAZARES, L. and SHELLHAMMER, P.F., Comparison of HER2-neu in prostate and breast carcinomas. Proc. Amer. Ass. Cancer Res., 36, 644A (1995).
27. WU, J.T., ASTILL, M.E. and ZHANG, P., Detection of the extracellular domain of c-erbB-2 oncoprotein in sera from patients with various carcinomas: correlation with tumor markers. J. clin. Lab. Anal., 7, 31-40 (1993).
28. YAMAMOTO, T., IKAWA, S., AKIYAMA, T., SEMBA, K., NOMURA, N., MIYAJIMA, N., SAITO, T. and TOYOSHIMA, K., Similarity of protein encoded by the human c-erbB-2 gene to epidermal growth factor receptor. Nature (Land.) 319, 230-234 (1986).
29. ZABRECKY, J.R., LAM, T., MCKENZIE, S.J. and CARNEY, W., The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells, SK-BR-3. J. biol. Chem., 266, 1716-1720 (1991).